People · Operator
Named in public records as an officer, director or promoter · active 2016–2017 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.7M | 2016 |
Luhan Yang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Luhan Yang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| PAUL SEKHRI | 1 | 7 |
| Bob More | 1 | 6 |
| Brad Smith | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Julie Sunderland | 1 | 5 |
| Geoff MacKay | 1 | 5 |
| Isaac Ciechanover | 1 | 5 |
| Sapna Srivastava | 1 | 3 |
| Rahul Kakkar | 1 | 3 |
| Boris Nikolic | 1 | 3 |
| Albert Wiegman | 1 | 2 |
| Michael Curtis | 1 | 2 |
| Kathleen Fanning | 1 | 2 |
| Stephen Gillis | 1 | 2 |
| PETER HANSON | 1 | 2 |
| Lucio L. Iannone | 1 | 1 |
| George M. Church | 1 | 1 |
| Sarah Schlesinger | 1 | 1 |
| Mark Pruzanski | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.